Related Experiment Videos
Penicillin failure and copathogenicity in streptococcal pharyngotonsillitis
1Department of Pediatrics, Georgetown University School of Medicine, Washington, DC.
The Journal of Family Practice
|February 1, 1994
Summary
Recurrent group A beta-hemolytic streptococcus (GABHS) pharyngotonsillitis is a clinical challenge. Beta-lactamase-producing bacteria protect GABHS from penicillin, leading to treatment failure.
Area of Science:
- Microbiology
- Infectious Diseases
- Otolaryngology
Background:
- Recurrent group A beta-hemolytic streptococcus (GABHS) pharyngotonsillitis poses a significant clinical challenge.
- Penicillin treatment failures in GABHS infections are linked to beta-lactamase-producing bacteria.
- These resistant organisms can protect susceptible pathogens, including GABHS, from penicillin therapy.
Purpose of the Study:
- To investigate the role of beta-lactamase-producing bacteria in recurrent GABHS pharyngotonsillitis.
- To understand the mechanisms by which these bacteria confer resistance.
- To highlight the need for targeted antimicrobial strategies.
Main Methods:
- Review of existing literature on GABHS pharyngotonsillitis and beta-lactamase-producing organisms.
- In vitro and in vivo studies examining the protective effects of beta-lactamase producers on GABHS.
- Analysis of clinical outcomes in patients with recurrent tonsillitis.
Main Results:
- Beta-lactamase-producing bacteria, including Staphylococcus aureus and Haemophilus species, are frequently found in inflamed tonsils.
- These organisms protect penicillin-susceptible GABHS from penicillin therapy both in vitro and in vivo.
- This protection contributes to increased penicillin failure rates in treating recurrent GABHS infections.
Conclusions:
- Recurrent GABHS pharyngotonsillitis treatment failures are associated with coinfection by beta-lactamase-producing bacteria.
- Effective eradication of GABHS requires antimicrobial agents that target both GABHS and beta-lactamase-producing organisms.
- Combined antimicrobial therapy offers a successful strategy for managing these challenging infections.